Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia

Leukemia Research

Volumn 33, Issue 7, 2009, Pages 891-897

  Xu, Zhifang ^a   Wang, Min ^a   Wang, Lin ^a   Wang, Yang ^a   Zhao, Xin ^a   Rao, Qing ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Acute leukemia; Hypermethylation; Methylation specific PCR; Quantitative PCR; TSC1; TSC2

Indexed keywords

MESSENGER RNA;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; BLOTTING, WESTERN; BONE MARROW; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, NUCLEIC ACID; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 67349208962     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.041     Document Type: Article

References (37)

1. The European chromosome 16 tuberous sclerosis consortium, Identification and characterisation of the tuberous sclearosis gene on chromosome. Cell 1993;16:1305-15.
2. Van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 5327 (1997) 805-808
3. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 15 (2003) 1829-1834
4. Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 7 (2001) 807-826
5. Catania M.G., Mischel P.S., and Vinters H.V. Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. J Neuropathol Exp Neurol 7 (2001) 711-723
6. Ghosh S., Tergaonkar V., Rothlin C.V., et al. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 3 (2006) 215-226
7. Ravitz M.J., Chen L., Lynch M., and Schmidt E.V. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer Res 23 (2007) 11209-11217
8. Zacharek S.J., Xiong Y., and Shumway S.D. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res 24 (2005) 11354-11360
9. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and independent pathways. Cancer Cell 2 (2003) 147-158
10. Soucek T., Pusch O., Wienecke R., DeClue J.E., and Hengstschläger M. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 272 (1997) 29301-29308
11. Fröhling S., Scholl C., Gilliland D.G., and Levine R.L. Genetics of myeloid malignancies-pathogenetic and clinical implications. J Clin Oncol 23 (2005) 6285-6295
12. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 (2005) 2527-2534
13. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 (1985) 620-625
14. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
15. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
16. Toshiyuki K., Shinji U., Jeremy P.C., et al. Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog. Mamm Genome 8 (1997) 554-558
17. Yeung R.S. Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer 38 (2003) 368-375
18. Wienecke R., Guha A., Maize Jr. J.C., et al. Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol 2 (1997) 230-235
19. Jiang W.G., Sampson J., Martin T.A., et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 11 (2005) 1628-1636
20. Kataoka K., Fujimoto K., Ito D., et al. Expression and prognostic value of tuberous sclerosis complex 2 gene product tuberin in human pancreatic cancer. Surgery 3 (2005) 450-455
21. Sales K.J., Battersby S., Williams A.R., Anderson R.A., and Jabbour H.N. Prostaglandin E2 mediates phosphorylation and down-regulation of the tuberous sclerosis-2 tumor suppressor (tuberin) in human endometrial adenocarcinoma cells via the Akt signaling pathway. J Clin Endocrinol Metab 12 (2004) 6112-6118
22. Gilliland D.G., and Tallman M.S. Focus on acute leukemias. Cancer Cell 1 (2002) 417-420
23. Min Y.H., Eom J.I., Cheong J.W., et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17 (2003) 995-997
24. Xu Q., Simpson S.E., Scialla T.J., Bagg A., and Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
25. Dan H.C., Sun M., Yang L., et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 38 (2002) 35364-35370
26. Burgstaller S., Rosner M., Lindengrün C., et al. Tuberin, p27 and mTOR in different cells. Amino Acids April (2008) [Epub ahead of print]
27. Hodges A.K., Li S., Maynard J., et al. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet 25 (2001) 2899-2905
28. Benvenuto G., Li S., Brown S.J., et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 54 (2000) 6306-6316
29. Chong Kopera H., Inoki K., Li Y., et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem 13 (2006) 8313-8316
30. Johnson M.W., Kerfoot C., Bushnell T., Li M., and Vinters H.V. Hamartin and tuberin expression in human tissues. Mod Pathol 3 (2001) 202-210
31. Lamb R.F., Roy C., Diefenbach T.J., et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2 May (5) (2000) 281-287
32. Xiao G.H., Shoarinejad F., Jin F., Golemis E.A., and Yeung R.S. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 272 March (10) (1997) 6097-6100
33. Morley M., Molony C.M., Weber T.M., et al. Genetic analysis of genome-wide variation in human gene expression. Nature 7001 (2004) 743-747
34. Mak B.C., Takemaru K., Kenerson H.L., Moon R.T., and Yeung R.S. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 278 February (8) (2003) 5947-5951
35. Anderson J.E., Kopecky K.J., Willman C.L., et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100 (2002) 3869-3876
36. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103 (2004) 479-485
37. Chakraborty S., Mohiyuddin S.M., Gopinath K.S., and Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer June (8) (2008) 163